ENSG00000153201 |
RANBP2 |
colorectal adenocarcinoma |
missense_variant |
4.921% (56/1138) |
3 entries |
ENSG00000153201 |
RANBP2 |
colorectal adenocarcinoma |
sequence_alteration |
4.921% (56/1138) |
1 entry |
ENSG00000153201 |
RANBP2 |
colorectal adenocarcinoma |
stop_gained |
4.921% (56/1138) |
1 entry |
ENSG00000153201 |
RANBP2 |
inflammatory myofibroblastic tumor |
gene_fusion |
50.0% (20/40) |
5 entries |
ENSG00000153201 |
RANBP2 |
colorectal adenocarcinoma |
frameshift_variant |
4.921% (56/1138) |
1 entry |
ENSG00000153201 |
RANBP2 |
cecum adenocarcinoma |
missense_variant |
8.0% (10/125) |
2 entries |
ENSG00000153201 |
RANBP2 |
bladder transitional cell carcinoma |
missense_variant |
2.19% (3/137) |
1 entry |
ENSG00000153201 |
RANBP2 |
colon adenocarcinoma |
frameshift_variant |
3.74% (27/722) |
2 entries |
ENSG00000153201 |
RANBP2 |
HER2 Positive Breast Carcinoma |
missense_variant |
4.43% (7/158) |
1 entry |
ENSG00000153201 |
RANBP2 |
clear cell renal carcinoma |
missense_variant |
2.248% (29/1290) |
1 entry |
ENSG00000153201 |
RANBP2 |
lung adenocarcinoma |
missense_variant |
2.541% (31/1220) |
5 entries |
ENSG00000153201 |
RANBP2 |
bile duct adenocarcinoma |
missense_variant |
1.058% (2/189) |
2 entries |
ENSG00000153201 |
RANBP2 |
osteosarcoma |
missense_variant |
2.586% (3/116) |
1 entry |
ENSG00000153201 |
RANBP2 |
cecum adenocarcinoma |
stop_gained |
8.0% (10/125) |
1 entry |
ENSG00000153201 |
RANBP2 |
esophageal squamous cell carcinoma |
missense_variant |
0.5926% (4/675) |
2 entries |
ENSG00000153201 |
RANBP2 |
large cell lung carcinoma |
missense_variant |
16.67% (3/18) |
2 entries |
ENSG00000153201 |
RANBP2 |
gastric intestinal type adenocarcinoma |
missense_variant |
5.882% (5/85) |
1 entry |
ENSG00000153201 |
RANBP2 |
brain glioblastoma |
sequence_alteration |
0.432% (4/926) |
2 entries |
ENSG00000153201 |
RANBP2 |
colon adenocarcinoma |
sequence_alteration |
3.74% (27/722) |
1 entry |
ENSG00000153201 |
RANBP2 |
basal cell carcinoma |
missense_variant |
12.07% (7/58) |
1 entry |
ENSG00000153201 |
RANBP2 |
myeloproliferative disorder |
gene_fusion |
25.0% (2/8) |
1 entry |
ENSG00000153201 |
RANBP2 |
gastric adenocarcinoma |
sequence_alteration |
4.122% (23/558) |
1 entry |
ENSG00000153201 |
RANBP2 |
melanoma |
missense_variant |
4.95% (5/101) |
2 entries |
ENSG00000153201 |
RANBP2 |
acute myeloid leukemia |
missense_variant |
1.87% (17/909) |
1 entry |
ENSG00000153201 |
RANBP2 |
colon adenocarcinoma |
missense_variant |
3.74% (27/722) |
5 entries |
ENSG00000153201 |
RANBP2 |
skin melanoma |
missense_variant |
4.24% (41/967) |
5 entries |
ENSG00000153201 |
RANBP2 |
esophageal adenocarcinoma |
sequence_alteration |
3.653% (16/438) |
1 entry |
ENSG00000153201 |
RANBP2 |
small cell lung carcinoma |
missense_variant |
2.769% (9/325) |
3 entries |
ENSG00000153201 |
RANBP2 |
hepatocellular carcinoma |
missense_variant |
1.778% (16/900) |
2 entries |
ENSG00000153201 |
RANBP2 |
skin melanoma |
sequence_alteration |
4.24% (41/967) |
1 entry |
ENSG00000153201 |
RANBP2 |
adenosquamous lung carcinoma |
missense_variant |
18.18% (2/11) |
1 entry |
ENSG00000153201 |
RANBP2 |
hemangioblastoma |
sequence_alteration |
9.375% (3/32) |
1 entry |
ENSG00000153201 |
RANBP2 |
rectal adenocarcinoma |
stop_gained |
3.167% (7/221) |
1 entry |
ENSG00000153201 |
RANBP2 |
prostate adenocarcinoma |
sequence_alteration |
1.994% (29/1454) |
1 entry |
ENSG00000153201 |
RANBP2 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
2.339% (4/171) |
1 entry |
ENSG00000153201 |
RANBP2 |
esophageal adenocarcinoma |
missense_variant |
3.653% (16/438) |
1 entry |
ENSG00000153201 |
RANBP2 |
squamous cell lung carcinoma |
missense_variant |
2.424% (20/825) |
2 entries |
ENSG00000153201 |
RANBP2 |
prostate adenocarcinoma |
missense_variant |
1.994% (29/1454) |
1 entry |
ENSG00000153201 |
RANBP2 |
skin melanoma |
stop_gained |
4.24% (41/967) |
1 entry |
ENSG00000153201 |
RANBP2 |
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.796% (3/167) |
2 entries |
ENSG00000153201 |
RANBP2 |
clear cell renal carcinoma |
sequence_alteration |
2.248% (29/1290) |
1 entry |
ENSG00000153201 |
RANBP2 |
rectal adenocarcinoma |
missense_variant |
3.167% (7/221) |
1 entry |
ENSG00000153201 |
RANBP2 |
prostate carcinoma |
missense_variant |
1.033% (5/484) |
2 entries |
ENSG00000153201 |
RANBP2 |
female breast carcinoma |
sequence_alteration |
1.023% (4/391) |
1 entry |
ENSG00000153201 |
RANBP2 |
clear cell renal carcinoma |
stop_gained |
2.248% (29/1290) |
1 entry |
ENSG00000153201 |
RANBP2 |
neoplasm of mature B-cells |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000153201 |
RANBP2 |
myelodysplastic syndrome |
gene_fusion |
1.316% (1/76) |
1 entry |
ENSG00000153201 |
RANBP2 |
Cervical Small Cell Carcinoma |
missense_variant |
33.33% (2/6) |
1 entry |
ENSG00000153201 |
RANBP2 |
prostate carcinoma |
sequence_alteration |
1.033% (5/484) |
1 entry |
ENSG00000153201 |
RANBP2 |
Liver Inflammatory Myofibroblastic Tumor |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000153201 |
RANBP2 |
gastric adenocarcinoma |
frameshift_variant |
4.122% (23/558) |
1 entry |
ENSG00000153201 |
RANBP2 |
neoplasm of mature B-cells |
stop_gained |
2.941% (1/34) |
1 entry |
ENSG00000153201 |
RANBP2 |
gastric intestinal type adenocarcinoma |
frameshift_variant |
5.882% (5/85) |
1 entry |
ENSG00000153201 |
RANBP2 |
Juvenile Myelomonocytic Leukemia |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000153201 |
RANBP2 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
2.339% (4/171) |
1 entry |
ENSG00000153201 |
RANBP2 |
endometrial carcinoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000153201 |
RANBP2 |
anaplastic astrocytoma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000153201 |
RANBP2 |
clear cell renal carcinoma |
frameshift_variant |
2.248% (29/1290) |
1 entry |
ENSG00000153201 |
RANBP2 |
Invasive Breast Carcinoma |
missense_variant |
2.174% (1/46) |
1 entry |
ENSG00000153201 |
RANBP2 |
colon carcinoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000153201 |
RANBP2 |
Pleural Epithelioid Mesothelioma |
missense_variant |
1.064% (1/94) |
1 entry |
ENSG00000153201 |
RANBP2 |
Cervical Small Cell Carcinoma |
sequence_alteration |
33.33% (2/6) |
1 entry |
ENSG00000153201 |
RANBP2 |
basal cell carcinoma |
frameshift_variant |
12.07% (7/58) |
1 entry |
ENSG00000153201 |
RANBP2 |
acute lymphoblastic leukemia |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000153201 |
RANBP2 |
angiosarcoma |
sequence_alteration |
7.692% (1/13) |
1 entry |
ENSG00000153201 |
RANBP2 |
gastric intestinal type adenocarcinoma |
conservative_inframe_deletion |
5.882% (5/85) |
1 entry |
ENSG00000153201 |
RANBP2 |
diffuse large B-cell lymphoma |
amino_acid_insertion |
0.9901% (3/303) |
1 entry |
ENSG00000153201 |
RANBP2 |
Uterine Carcinosarcoma |
missense_variant |
2.727% (3/110) |
1 entry |
ENSG00000153201 |
RANBP2 |
esophageal adenocarcinoma |
frameshift_variant |
3.653% (16/438) |
1 entry |
ENSG00000153201 |
RANBP2 |
nasopharyngeal squamous cell carcinoma |
stop_gained |
1.796% (3/167) |
1 entry |
ENSG00000153201 |
RANBP2 |
lung adenocarcinoma |
stop_gained |
2.541% (31/1220) |
1 entry |
ENSG00000153201 |
RANBP2 |
diffuse large B-cell lymphoma |
stop_gained |
0.9901% (3/303) |
1 entry |
ENSG00000153201 |
RANBP2 |
laryngeal squamous cell carcinoma |
missense_variant |
3.846% (1/26) |
1 entry |
ENSG00000153201 |
RANBP2 |
female breast carcinoma |
frameshift_variant |
1.023% (4/391) |
1 entry |
ENSG00000153201 |
RANBP2 |
skin melanoma |
frameshift_variant |
4.24% (41/967) |
1 entry |
ENSG00000153201 |
RANBP2 |
rectal adenocarcinoma |
frameshift_variant |
3.167% (7/221) |
1 entry |
ENSG00000153201 |
RANBP2 |
laryngeal squamous cell carcinoma |
sequence_alteration |
3.846% (1/26) |
1 entry |
ENSG00000153201 |
RANBP2 |
diffuse large B-cell lymphoma |
missense_variant |
0.9901% (3/303) |
1 entry |
ENSG00000153201 |
RANBP2 |
Pleural Biphasic Mesothelioma |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000153201 |
RANBP2 |
papillary thyroid carcinoma |
missense_variant |
0.2532% (1/395) |
1 entry |
ENSG00000153201 |
RANBP2 |
Gallbladder Adenocarcinoma |
sequence_alteration |
1.149% (1/87) |
1 entry |
ENSG00000153201 |
RANBP2 |
brain glioblastoma |
missense_variant |
0.432% (4/926) |
1 entry |
ENSG00000153201 |
RANBP2 |
Retroperitoneal Inflammatory Myofibroblastic Tumor |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000153201 |
RANBP2 |
Kidney Oncocytoma |
missense_variant |
3.125% (1/32) |
1 entry |
ENSG00000153201 |
RANBP2 |
Merkel cell skin cancer |
missense_variant |
3.226% (1/31) |
1 entry |
ENSG00000153201 |
RANBP2 |
non-small cell lung carcinoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000153201 |
RANBP2 |
osteosarcoma |
sequence_alteration |
2.586% (3/116) |
1 entry |
ENSG00000153201 |
RANBP2 |
acute myeloid leukemia |
gene_fusion |
1.87% (17/909) |
1 entry |
ENSG00000153201 |
RANBP2 |
metaplastic breast carcinoma |
missense_variant |
3.922% (2/51) |
1 entry |
ENSG00000153201 |
RANBP2 |
Pancreatic Acinar Cell Carcinoma |
missense_variant |
5.0% (1/20) |
1 entry |
ENSG00000153201 |
RANBP2 |
Ampulla of Vater Carcinoma |
missense_variant |
1.176% (1/85) |
1 entry |
ENSG00000153201 |
RANBP2 |
female breast carcinoma |
missense_variant |
1.023% (4/391) |
1 entry |
ENSG00000153201 |
RANBP2 |
chronic lymphocytic leukemia |
frameshift_variant |
0.2252% (2/888) |
1 entry |
ENSG00000153201 |
RANBP2 |
oral squamous cell carcinoma |
missense_variant |
0.4878% (1/205) |
1 entry |
ENSG00000153201 |
RANBP2 |
head and neck squamous cell carcinoma |
missense_variant |
0.1597% (1/626) |
1 entry |
ENSG00000153201 |
RANBP2 |
hemangioblastoma |
missense_variant |
9.375% (3/32) |
1 entry |
ENSG00000153201 |
RANBP2 |
T-cell acute lymphoblastic leukemia |
missense_variant |
0.2632% (1/380) |
1 entry |
ENSG00000153201 |
RANBP2 |
hepatocellular carcinoma |
frameshift_variant |
1.778% (16/900) |
1 entry |